Hydrocodone/ibuprofen

Last updated

Hydrocodone/ibuprofen
Combination of
Hydrocodone Opioid analgesic
Ibuprofen Non-steroidal anti-inflammatory drug
Clinical data
Trade names Ibudone, Reprexain, Vicoprofen
AHFS/Drugs.com Professional Drug Facts
MedlinePlus a601006
License data
Dependence
liability 		Moderate
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability >80%
Metabolism for hydrocodone: liver, CYP3A4; for ibuprofen: liver, CYP2C9
Elimination half-life for hydrocodone: 228-294 mins (3.8-4.9 hrs); for ibuprofen: 108-120 mins (1.8-2 hrs)
Excretion for hydrocodone: urinary; for ibuprofen: urine primarily (<1% unchanged)
Identifiers
KEGG
CompTox Dashboard (EPA)
   (verify)
Generic hydrocodone/ibuprofen 7.5/200 mg Hydrocodonebtibu75200.jpeg
Generic hydrocodone/ibuprofen 7.5/200 mg

Hydrocodone/ibuprofen (INNs), sold under the brand name Vicoprofen, is a fixed-dose combination analgesic medication used in short-term therapy to relieve severe pain. [3] [4] Vicoprofen combines the analgesic and antitussive properties of hydrocodone with the analgesic, anti-inflammatory, and antipyretic properties of ibuprofen. [1] In contrast to hydrocodone/acetaminophen combination analgesics such as Vicodin, this hydrocodone/ibuprofen avoids some of the liver toxicity which may occur from acetaminophen, but still presents significant dangers in hydrocodone overdose, namely respiratory depression. Vicoprofen is supplied in a fixed dose combination tablet which contains hydrocodone bitartrate, USP 7.5 mg with ibuprofen, USP 200 mg. Additional strengths of generic Vicoprofen are now available, in combinations of 5 mg/200 mg and 10 mg/200 mg respectively. [5]

Contents

Medical uses

Hydrocodone/ibuprofen has a labeled indication for "short-term (generally <10 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate". [5] [1]

Pregnancy

Opioids such as hydrocodone cross the placenta, and can therefore affect the fetus. Studies have shown a possible association between opioids and adverse outcomes such as birth defects, poor fetal growth, stillbirth, and preterm delivery. Prolonged use of opioids by a pregnant mother can also lead to neonatal withdrawal syndrome. [5] [6] NSAIDs such as ibuprofen should generally be avoided in pregnancy, as there are conflicting reports of birth defects after in utero exposure. However, it is accepted that NSAIDs prevent closure of the fetal ductus arteriosus, which happens during the later stages of pregnancy. Because of this, ibuprofen should be avoided after 30 weeks gestation. [5] [6]

Breastfeeding

Hydrocodone and ibuprofen are excreted in breast milk, so appropriate caution should be taken when prescribing to breastfeeding mothers. [5] [6]

Special populations

There is no evidence to support altered pharmacokinetic properties due to differences in gender or age. However, this drug combination has not been tested in children. [1]

Adverse effects

The side effects for hydrocodone/ibuprofen are a combination of the side effects of the component drugs. Side effects experienced in more than 10% of the population taking the drug include: headache, drowsiness, dizziness, constipation, nausea, and dyspepsia. [5]

In the US, the label for hydrocodone/ibuprofen contains a black box warning about addiction, abuse, and misuse. [1] [2]

Pharmacology

Pharmacokinetics

The two active components of the drug, ibuprofen and hydrocodone, do not affect each other's absorption characteristics or other pharmacokinetic parameters. [1] After an oral dose, the peak level of hydrocodone in the blood is reached 1.7 hours after administration. [1] The blood levels of ibuprofen peak 1.8 hours after oral administration. [1]

History

Discovery and development

The patent for Vicoprofen was filed in December 1984, and U.S. patent number 4,587,252 was granted in May 1986. [7] Although ibuprofen and hydrocodone were already available on the market at this time, the fact that they had never been supplied together in a single formulation required approval from the FDA as if it were a new drug. Knoll filed an investigational new drug application on 30 December 1986. A new drug application was later filed by Knoll on 25 April 1996, and received final approval from the FDA on 23 September 1997. [8] Vicoprofen tablets were initially formulated and packaged by Knoll, with ibuprofen supplied by Albemarle Corporation and hydrocodone supplied by Mallinckrodt Pharmaceuticals. [9]

The validity of Knoll's patent on Vicoprofen has been challenged in federal court. In September 2002, the U.S. District Court for the Norther District of Illinois granted a motion of invalidity filed by Teva Pharmaceuticals against Knoll's patent on Vicoprofen, ruling the patent was invalid as obvious. [10] This ruling paved the way for Teva's abbreviated new drug application to be approved by the FDA which would allow them to manufacture and market their own generic. [11] Knoll appealed the decision. In April 2003, Teva announced that its abbreviated new drug application had been approved by the FDA, and its generic would begin shipping immediately. [11] In May 2004, the United States Court of Appeals for the Federal Circuit vacated the previous judgment by the U.S. District Court for the Northern District of Illinois, and the case was remanded back for further court proceedings. Teva continued to sell its generic during this time. [12] The patent for Vicoprofen expired on 18 December 2004, officially opening the drug to generic manufacture. [7] In July 2016, the FDA approved another generic equivalent, manufactured by Aurobindo Pharma Limited. [13]

Ownership and promotion

Knoll pharmaceuticals, originally founded in Germany in 1886, became a subsidiary of BASF (a German chemical company) in 1975. [14] It was under their control when Vicoprofen was originally developed and approved. In March 2000, Knoll Pharmaceuticals and Abbott Laboratories, an American health care company, announced a co-promotion agreement for Vicoprofen, in which Abbott would promote Vicoprofen to its network of buyers, including physicians, hospitals, and surgical centers. [15] In June 2002, Abbott Laboratories, paid $6.9 billion to acquire the entire Knoll pharmaceutical unit from BASF, including Vicoprofen. [16]

DEA classification

Vicoprofen was originally approved as a schedule III drug, but was later reclassified to a schedule II drug based on the DEA reclassification of hydrocodone containing products effective 6 October 2014. [17]

Research

The new drug application for Vicoprofen was approved based on data from both single and multiple dose analgesia trials.

The single dose analgesia studies occurred in multiple surgical settings, including dental, back, and abdominal/gynecologic surgery in the U.S. and Puerto Rico. There were 1,537 patients enrolled over all trials, with 79% of the participants being female. There were 10 single dose analgesia trials included in the new drug application. All studies were similarly designed: after completion of a procedure in which pain was rated as moderate or severe, patients would be randomized into various treatment groups. The treatment groups included: ibuprofen only, hydrocodone only, Vicoprofen (hydrocodone/ibuprofen), and placebo. The participant's pain would then be tracked over the next several hours by the self reporting of pain scores. [1]

There were four multiple dose trials included in the new drug application. These studies were all completed in the U.S., in settings including burn unit, post-operatively, and chronic pain settings. A total of 683 patients were enrolled in all of the multiple dose trials, with 57% of the participants being women. These studies also looked at self reported pain intensities over a 5-day period of multiple dosing. In these studies, patients were either given the trial drug Vicoprofen or one of two an active controls: codeine with acetaminophen (Tylenol #3) or oxycodone with acetaminophen (Percocet), depending on the trial. Patients were allowed to take a dose as needed but no more than every 4 to 6 hours for up to 5 days. These trials measured efficacy based on parameters including self reported pain scores, number of doses used, and duration of treatment. [1]

Society and culture

Cost

The average wholesale price (AWP) of generic Vicoprofen varies based on the strength of the preparation. Pricing data gathered from Lexicomp in October 2017 indicates the AWP for a 100 count bottle of 7.5 mg/200 mg strength to be $114.62, a 100 count of 5 mg/200 mg strength to be $356.62 and a 100 count of 10 mg/200 mg strength to be $470.35. [5] These prices are all for generic equivalents of Vicoprofen.

Utilization

In 2003, at the time of the approval announcement for the first generic equivalent, it was reported that annual sales of brand name Vicoprofen totaled $104 million. [11] According to IMS, the hydrocodone/ibuprofen tablets 7.5 mg/200 mg, had an estimated market size of $15.7 million for the 12 months preceding May 2016. [18]

See also

Related Research Articles

<span class="mw-page-title-main">Hydrocodone</span> Opioid drug used in pain relief

Hydrocodone, also known as dihydrocodeinone, is a semisynthetic opioid used to treat pain and as a cough suppressant. It is taken by mouth. Typically it is dispensed as the combination acetaminophen/hydrocodone or ibuprofen/hydrocodone for pain severe enough to require an opioid and in combination with homatropine methylbromide to relieve cough. It is also available by itself in a long-acting form under the brand name Zohydro ER, among others, to treat severe pain of a prolonged duration. Hydrocodone is a controlled drug: in the United States a Schedule II Controlled Substance.

<span class="mw-page-title-main">Oxycodone</span> Opioid medication

Oxycodone, sold under various brand names such as Roxicodone and OxyContin, is a semi-synthetic opioid used medically for treatment of moderate to severe pain. It is highly addictive and is a commonly abused drug. It is usually taken by mouth, and is available in immediate-release and controlled-release formulations. Onset of pain relief typically begins within fifteen minutes and lasts for up to six hours with the immediate-release formulation. In the United Kingdom, it is available by injection. Combination products are also available with paracetamol (acetaminophen), ibuprofen, naloxone, naltrexone, and aspirin.

<span class="mw-page-title-main">Paracetamol</span> Common medication for pain and fever

Paracetamol is a non-opioid analgesic and antipyretic agent used to treat fever and mild to moderate pain. It is a widely used over the counter medication. Common brand names include Tylenol and Panadol.

<span class="mw-page-title-main">Ibuprofen</span> Medication used for treating pain, fever, and inflammation

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that is used to relieve pain, fever, and inflammation. This includes painful menstrual periods, migraines, and rheumatoid arthritis. It may also be used to close a patent ductus arteriosus in a premature baby. It can be used orally or intravenously. It typically begins working within an hour.

Oxycodone/aspirin is a combination drug marketed by Endo Pharmaceuticals. It is a tablet containing a mixture of 325 mg of aspirin and 4.8355 mg of oxycodone HCl ; it is an opioid/non-opioid combination used to treat moderate to moderately severe pain. The safety of the combination during pregnancy has not been established, although aspirin is generally contraindicated during pregnancy, and the drug has been placed in pregnancy category D. Inactive ingredients include D&C Yellow 10, FD&C Yellow 6, microcrystalline cellulose, and corn starch. Percodan was first marketed by DuPont Pharmaceuticals and prescribed in the United States in 1950. Once a widely prescribed painkiller, it has largely been replaced by alternative oxycodone compounds containing paracetamol (acetaminophen) instead of aspirin, such as Percocet.

Oxycodone/paracetamol, sold under the brand name Percocet among others, is a fixed-dose combination of the opioid oxycodone with paracetamol (acetaminophen), used to treat moderate to severe pain.

<span class="mw-page-title-main">Oxymorphone</span> Opioid analgesic drug

Oxymorphone is a highly potent opioid analgesic indicated for treatment of severe pain. Pain relief after injection begins after about 5–10 minutes, after oral administration it begins after about 30 minutes, and lasts about 3–4 hours for immediate-release tablets and 12 hours for extended-release tablets. The elimination half-life of oxymorphone is much faster intravenously, and as such, the drug is most commonly used orally. Like oxycodone, which metabolizes to oxymorphone, oxymorphone has a high potential to be abused.

<span class="mw-page-title-main">Dihydrocodeine</span> Opioid

Dihydrocodeine is a semi-synthetic opioid analgesic prescribed for pain or severe dyspnea, or as an antitussive, either alone or compounded with paracetamol (acetaminophen) or aspirin. It was developed in Germany in 1908 and first marketed in 1911.

<span class="mw-page-title-main">Dipipanone</span> Opioid analgesic drug

Dipipanone, sold under the brand names of Pipadone and Diconal is a strong opioid analgesic drug, used for acute pain by mouth (PO) for adults. It is often used in instances where morphine is indicated but cannot be used due to the patient being allergic to morphine. In analgesic potency 25 mg dipipanone is approximately equivalent to 10 mg morphine.

<span class="mw-page-title-main">Teva Pharmaceuticals</span> Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals. Teva Pharmaceuticals was the largest generic drug manufacturer, when it was surpassed briefly by US-based Pfizer. Teva regained its market leader position once Pfizer spun off its generic drug division in a merger with Mylan, forming the new company Viatris at the end of 2020. Overall, Teva is the 18th largest pharmaceutical company in the world.

<span class="mw-page-title-main">Hydrocodone/paracetamol</span> Combination pain relief drug

Hydrocodone/paracetamol is the combination of the pain medications hydrocodone and paracetamol (acetaminophen). It is used to treat moderate to severe pain. It is taken by mouth. Recreational use is common in the United States.

<span class="mw-page-title-main">Codeine</span> Opiate and prodrug of morphine used to treat pain

Codeine is an opiate and prodrug of morphine mainly used to treat pain, coughing, and diarrhea. It is also commonly used as a recreational drug. It is found naturally in the sap of the opium poppy, Papaver somniferum. It is typically used to treat mild to moderate degrees of pain. Greater benefit may occur when combined with paracetamol (acetaminophen) or a nonsteroidal anti-inflammatory drug (NSAID) such as aspirin or ibuprofen. Evidence does not support its use for acute cough suppression in children or adults. In Europe, it is not recommended as a cough medicine in those under 12 years of age. It is generally taken by mouth. It typically starts working after half an hour, with maximum effect at two hours. Its effects last for about four to six hours. Codeine exhibits abuse potential similar to other opioid medications, including a risk of habituation and overdose.

Encaprin was a brand of safety-coated aspirin capsules made by Procter & Gamble in the mid-1980s through its Norwich Eaton Pharmaceuticals division. In 1986, the brand was involved in a cyanide poisoning hoax, and its sales never recovered.

<span class="mw-page-title-main">Tapentadol</span> Opioid analgesic of benzenoid class

Tapentadol, brand names Nucynta among others, is a centrally acting opioid analgesic of the benzenoid class with a dual mode of action as an agonist of the μ-opioid receptor and as a norepinephrine reuptake inhibitor (NRI). Analgesia occurs within 32 minutes of oral administration, and lasts for 4–6 hours.

<span class="mw-page-title-main">Dezocine</span> Opioid analgesic

Dezocine, sold under the brand name Dalgan, is an atypical opioid analgesic which is used in the treatment of pain. It is used by intravenous infusion and intramuscular injection.

<span class="mw-page-title-main">Omega-3 acid ethyl esters</span>

Omega-3-acid ethyl esters are a mixture of ethyl eicosapentaenoic acid and ethyl docosahexaenoic acid, which are ethyl esters of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) found in fish oil. Together with dietary changes, they are used to treat high blood triglycerides which may reduce the risk of pancreatitis. They are generally less preferred than statins, and use is not recommended by NHS Scotland as the evidence does not support a decreased risk of heart disease. Omega-3-acid ethyl esters are taken by mouth.

An equianalgesic chart is a conversion chart that lists equivalent doses of analgesics. Equianalgesic charts are used for calculation of an equivalent dose between different analgesics. Tables of this general type are also available for NSAIDs, benzodiazepines, depressants, stimulants, anticholinergics and others.

Ibuprofen/paracetamol, is a fixed-dose combination of two medications, ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), and paracetamol (acetaminophen). It is available as a generic medication and common brand names include Combiflam.

<span class="mw-page-title-main">Benzhydrocodone</span> Chemical compound

Benzhydrocodone (INN) is an opioid prodrug of the morphinan class. Its chemical structure consists of hydrocodone coupled with benzoic acid. Benzhydrocodone itself is inactive and acts as a prodrug to hydrocodone upon cleavage of the benzoate portion of the molecule.

Oxycodone/ibuprofen is an oral combination drug formulation of the opioid analgesic oxycodone and the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen that is used in the treatment of chronic and acute pain. This particular drug is supplied in a fixed dose combination tablet which contains Oxycodone Hydrochloride, USP 5 mg with Ibuprofen, USP 400 mg.

References

  1. 1 2 3 4 5 6 7 8 9 10 "Vicoprofen- hydrocodone bitartrate and ibuprofen tablet, coated". DailyMed. 12 August 2011. Retrieved 6 September 2020.
  2. 1 2 "Reprexain- hydrocodone bitartrate, ibuprofen tablet, film coated; Reprexain- hydrocodone bitartrate, ibuprofen tablet". DailyMed. 27 October 2009. Retrieved 23 December 2023.
  3. ↑ "Hydrocodone and Ibuprofen (Professional Patient Advice)". Drugs.com. 20 May 2020. Retrieved 6 September 2020.
  4. ↑ "Vicoprofen: Uses, Dosage & Side Effects". Drugs.com. 24 June 2019. Retrieved 6 September 2020.
  5. 1 2 3 4 5 6 7 "Hydrocodone/Ibuprofen". online.lexi.com. 17 October 2017. Retrieved 27 October 2017.
  6. 1 2 3 "Hydrocodone / ibuprofen Use During Pregnancy". Drugs.com. 20 November 2019. Retrieved 6 September 2020.
  7. 1 2 "United States Court of Appeals for the Federal Circuit - The Arnold Partnership v. Jon Dudas". www.uspto.gov. 24 March 2004. Archived from the original on 7 November 2017. Retrieved 27 October 2017.
  8. ↑ "Approval Package for NDA 20716" (PDF). www.fda.gov. 23 September 1997. Retrieved 27 October 2017.
  9. ↑ Yaciw C (18 November 1996). "NDA 20716 Chemistry Review" (PDF). www.fda.gov. Retrieved 27 October 2017.
  10. ↑ Teva Pharmaceuticals (12 September 2002). "Judge Grants Teva Summary Judgment of Invalidity for Patent Related to Hydrocodone Bitartrate and Ibuprofen Tablets". Press Release. Archived from the original on 7 November 2017. Retrieved 27 October 2017.
  11. 1 2 3 Teva Pharmaceuticals (14 April 2003). "Teva Announces Approval of Hydrocodone Bitartrate and Ibuprofen Tablets". Press Release. Archived from the original on 25 December 2018. Retrieved 27 October 2017.
  12. ↑ Teva Pharmaceuticals (19 May 2004). "Teva Comments On The Court Of Appeals Decision Regarding Generic Version Of Vicoprofen®". Press Release. Archived from the original on 7 November 2017. Retrieved 27 October 2017.
  13. ↑ Aurobindo LTD (May 2016). "Aurobindo receives final FDA Approval for Hydrocodone Bitartrate and Ibuprofen Tablets (C-II)". Press Release. Retrieved 27 October 2017.
  14. ↑ BASF Corporation (15 December 2000). "Pharma Business Sold for 6.9 Billion". BASF Press Release. Archived from the original on 12 February 2013. Retrieved 27 October 2017.
  15. ↑ "Abbott And Knoll Sign Co-Promotion Agreement". www.evaluategroup.com. 3 March 2000. Retrieved 27 October 2017.
  16. ↑ Burton TM (15 December 2000). "Abbott Laboratories Agrees to Buy BASF's Knoll Pharmaceutical Unit". Wall Street Journal. ISSN   0099-9660 . Retrieved 31 October 2017.
  17. ↑ "Schedules of Controlled Substances: Rescheduling of Hydrocodone Combination Products From Schedule III to Schedule II". www.usdoj.gov. 22 August 2014. Archived from the original on 7 September 2014. Retrieved 27 October 2017.
  18. ↑ "Aurobindo receives final FDA Approval for Hydrocodone Bitartrate and Ibuprofen Tablets (C-II)". www.aurobindousa.com/. May 2016. Retrieved 27 October 2017.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.